Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300014 | 1.00 | TAAR1 (0.59) | TAAR1AOC3SIGMAR1MEN1NPC1 | |
| SCHEMBL5548324 | 0.88 | AOC3 (0.58) | TAAR1AOC3SIGMAR1 | |
| SCHEMBL5535244 | 0.86 | SIGMAR1 (0.61) | TAAR1AOC3SIGMAR1FDPS | |
| SCHEMBL17715348 | 0.85 | SIGMAR1 (0.65) | TAAR1AOC3SIGMAR1FDPS | |
| SCHEMBL17715342 | 0.85 | SIGMAR1 (0.65) | TAAR1AOC3SIGMAR1FDPS | |
| SCHEMBL17715343 | 0.85 | SIGMAR1 (0.65) | TAAR1AOC3SIGMAR1FDPS | |
| SCHEMBL5544017 | 0.85 | SIGMAR1 (0.65) | TAAR1AOC3SIGMAR1FDPS | |
| SCHEMBL5543664 | 0.85 | SIGMAR1 (0.65) | TAAR1AOC3SIGMAR1FDPS | |
| SCHEMBL17715347 | 0.85 | SIGMAR1 (0.65) | TAAR1AOC3SIGMAR1FDPS | |
| Dimethylformamide SCHEMBL8332170 | 0.80 | TAAR1 (0.54) | TAAR1AOC3SIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | OPRL1, ORMDL3, OGFRL1 | TAAR1 560/4885AOC3 382/4885SIGMAR1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.